Ivabradine vs Placebo: Primary Composite Endpoint
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
Measures 6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note | Source |
|---|---|---|---|---|---|---|
| Risk in group 1 | 0.0685 | 0.0636 | 0.0737 | wilson | ClinicalTrials.gov | |
| Risk in group 2 | 0.064 | 0.0592 | 0.0691 | wilson | ClinicalTrials.gov | |
| Risk difference, group 1 minus group 2 | 0.00452 | -0.00254 | 0.0116 | newcombe hybrid score | ClinicalTrials.gov | |
| Risk ratio, group 1 over group 2 | 1.07 | 0.962 | 1.19 | log | ClinicalTrials.gov | |
| Odds ratio, group 1 over group 2 | 1.08 | 0.96 | 1.21 | log | ClinicalTrials.gov | |
| Number needed to treat, for one more participant with the outcome on Ivabradine than on Placebo | 221 | from the risk difference interval | the interval includes no difference | ClinicalTrials.gov |
Groups 2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code | Source |
|---|---|---|---|---|---|---|
| Group 1 | Ivabradine | Ivabradine: 5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months. | 654 | 9,550 | OG000 | ClinicalTrials.gov |
| Group 2 | Placebo | Placebo: Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months. | 611 | 9,552 | OG001 | ClinicalTrials.gov |
Outcome 5
| Field | Value | Source |
|---|---|---|
| Type | PRIMARY | ClinicalTrials.gov |
| Title | Primary Composite Endpoint | ClinicalTrials.gov |
| Description | First event among cardiovascular death or non-fatal myocardial infarction | ClinicalTrials.gov |
| Time frame | The events are expressed as the time to occurrence of the first event, defined as the duration between the date of randomisation and the date of first occurrence of event, assessed up to 48 months. | ClinicalTrials.gov |
| Population | ClinicalTrials.gov |
Trial 8
| Field | Value | Source |
|---|---|---|
| Title | Effects of Ivabradine in Patients With Stable Coronary Artery Disease Without Clinical Heart Failure | ClinicalTrials.gov |
| NCT number | NCT02446990 | ClinicalTrials.gov |
| Phases | PHASE3 | ClinicalTrials.gov |
| Conditions | Coronary Artery Disease | ClinicalTrials.gov |
| Interventions | Ivabradine, Placebo | ClinicalTrials.gov |
| Lead sponsor | Institut de Recherches Internationales Servier | ClinicalTrials.gov |
| Results first posted | 2015-06-25 | ClinicalTrials.gov |
| Results on ClinicalTrials.gov | https://clinicaltrials.gov/study/NCT02446990?tab=results | ClinicalTrials.gov |
Source 4
| Field | Value | Source |
|---|---|---|
| Release | trial-comparisons-2026-03-23-0.1.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57 | ClinicalTrials.gov |
| AACT copy | 2026-03-23 | ClinicalTrials.gov |
| Tables read | outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet | ClinicalTrials.gov |
Release trial-comparisons-2026-03-23-0.1.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.